Matinas BioPharma Holdings Inc. (AMEX:MTNB) saw an upside of 3.05% to $0.17 after adding $0.01 on Tuesday. The 5-day average trading volume is 626,832 shares of the company’s common stock. It has gained $0.2000 in the past week and touched a new high 3 times within the past 5 days. An average of 1,057,728 shares of the company has been traded in the last 20 days, and the 50-day average volume stands at 700,509.
MTNB’s 1-month performance is -55.78% or -$0.2301 on its low of $0.1103 reached on 08/10/23. The company’s shares have touched a 52-week low of $0.11 and high of $0.89, with the stock’s rally to the 52-week high happening on 04/20/23. YTD, MTNB has lost -66.20% or -$0.3301 and has reached a new high 13 times. However, the current price is down -81.01% from the 52-week high price.
Top 5 AI Stocks to Buy for 2023
The artificial intelligence (AI) revolution is already here. And it's about to change everything we know about everything.
According to Grand View Research, the global AI boom could grow from about $137 billion in 2022 to more than $1.81 trillion by 2030. And investors like you always want to get in on the hottest stocks of tomorrow. Here are five of the best ways to profit from the AI boom.
Click Here to Download the FREE Report.
Sponsored
Valuation Metrics
MTNB stock has a beta of 2.08. Moving on to other valuation ratios, the trailing price-to-sales (P/S) ratio is 8.69.
Matinas BioPharma Holdings Inc.’s quick ratio for the period ended June 29 was 9.30. The trailing 12-month EBITDA margin is -743.16%. The firm’s gross profit as reported stood at $27.78 million against revenue of $3.19 million.
Earnings Surprise
For the quarterly period ending June 29 this year, Net income grew 2.31% to -$6.06 million, while revenue of -$5.51 million was 9.08% off the previous quarter. Analysts expected MTNB to announce -$0.03 per share in earnings in its latest quarter, but it posted -$0.03, representing a 0.00% surprise. EBITDA for the quarter stood at more than -$5.9 million. MTNB stock balance sheet for the quarter ending June 29 shows that total liabilities totaled 6.17 million, with total debt at $3.85 million. Shareholders hold equity totaling $217.26 million.
Let’s look briefly at Matinas BioPharma Holdings Inc. (MTNB) price momentum from a technical analysis perspective. The 9-day relative strength index as at close on 21 August was 19.73% to suggest the stock is trending oversold, with historical volatility in this time period at 256.37%.
The stock’s 5-day moving average is $0.1658, reflecting a +4.94% or $0.0080 change from its current price. MTNB is currently trading -57.53% above its 20-day SMA, -62.62% above its 100-day SMA. However, the stock’s current price level is away from the SMA50 by -54.35% and SMA200 by-78.35%.
Stochastic %K and %D was 21.87% and 20.85% and the average true range (ATR) pointed at 0.0318. The RSI (14) points at 22.96%, while the 14-day stochastic is at 23.76% with the period’s ATR at 0.0331. The stock’s 9-day MACD Oscillator is pointing at -0.0030 and -0.0618 on the 14-day charts.
Analyst Ratings
In the most recent analyst report for Matinas BioPharma Holdings Inc. (AMEX: MTNB), Piper Sandler downgraded it to a Neutral rating. They previously had an Overweight rating on the stock.
